Latest news for Genesis Healthcare (OTC:GENN) Stock

Genesis Healthcare Inc is a post-acute care provider in the United States. It focuses on the medical and physical issues facing elderly patients and is provided by the employees of skilled nursing facilities, assisted/senior living communities, integrated and third-party rehabilitation therapy business. The company has three operating segments. The inpatient services segment include the operation of skilled nursing facilities and assisted/senior living facilities; rehabilitation therapy segment services include integrated and third-party rehabilitation and respiratory therapy services; and all other services. The majority of its revenue is generated from its skilled nursing facilities of the inpatient services segment.

GENESIS HEALTHCARE INC A by Genesis Healthcare, Inc.

Genesis Healthcare Inc

3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) stock surged after the company reported better-than-expected fourth-quarter 2024 results and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43092130/3m-reports-fourth-quarter-and-full-year-2024-results-initiates-full-year-2025-financial-guidance" rel="noreferrer noopener">initiated 2025 guidance.</a>
The company reported net sales of $6.01 billion, a slight increase of 0.13% year-over-year. Adjusted net sales totaled $5.808 billion, up 2.2% YoY, beating the consensus of $5.781 billion.
Adjusted EPS was $1.68, down 2% YoY, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus of $1.66.</a>
Adjusted organic sales growth for the quarter was 2.1%, reflecting a 70-basis-point headwind due to product portfolio optimization initiatives and the exit from certain smaller markets.
GAAP operating income margin expanded to 18.1% from 15% a year-ago. Adjusted operating margin contracted 17 bps points to 19.7%, with adjusted business segment operating income of $1.14 billion (+1.3% YoY).
Safety &amp; Industrial reported 2.4% adjusted organic growth and adjusted operating margin expansion to 21% from 19.7% in the prior year quarter.
Transportation &amp; Electronics reported 2% adjusted organic growth, and the adjusted operating margin contracted to 19.4% from 20.9% a year ago. The consumer segment reported adjusted organic growth of 1.2%.
Operating cash flow for full-year 2024 stood at $1.8 billion, down from $6.68 billion. MMM returned $3.8 billion to shareholders via dividends and share repurchases.
Operating cash flow included $3.8 billion in net after-tax payments for significant litigation costs, primarily associated with Public Water Systems and Combat Arms Earplugs.
2025 Guidance: 3M anticipates adjusted total sales growth of 0.5% to 1.5%, driven by adjusted organic sales <a href="https://www.benzinga.com/calendars/guidance">growth of 2% to 3%.</a>
The company projects adjusted EPS in the range of $7.60 to $7.90 versus consensus of $7.78 and expects adjusted operating cash flow between $5.2 billion and $5.3 billion, resulting in approximately 100% adjusted free cash flow conversion.
Price Action: MMM shares are trading higher by 4.23% at $147 premarket on the last check Tuesday.

Earnings

Equities

News

Guidance

Movers

Post-It Maker 3M Q4 Earnings: Revenue And EPS Beat, Expands Margins, Optimistic 2025 Guidance And More

Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) will release its second-quarter financial results, after the <a href="https://www.benzinga.com/quote/STX/earnings">closing bell, on Tuesday, Jan. 21, 2025.</a>
Analysts expect the Singapore-based company to report quarterly earnings at $1.88 per share, up sharply from 12 cents per share in the year-ago period. Seagate projects quarterly revenue of $2.32 billion, compared to $1.55 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 16, Wells Fargo analyst Aaron Rakers maintained Seagate with an Equal-Weight rating and lowered the price target from $120 to $110.
With the recent buzz around Seagate, some investors may be eyeing potential gains from the company's dividends, too. As of now, Seagate offers an annual dividend yield of 2.95%, which is a quarterly dividend amount of 72 cents per share ($2.88 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $203,447 or around 2,083 shares. For a more modest $100 per month or $1,200 per year, you would need $40,728 or around 417 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.88 in this case). So, $6,000 / $2.88 = 2,083 ($500 per month), and $1,200 / $2.88 = 417 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
STX Price Action: Shares of Seagate gained 2.7% to close at $97.67 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Seagate Stock Ahead Of Q2 Earnings

JP Morgan analyst Richard Shane maintains Ares Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRE#NYSE">ACRE</a>) with a Neutral and lowers the price target from $7 to $6.

Price Target

Analyst Ratings

ACRE

JP Morgan Maintains Neutral on Ares Comml Real Est, Lowers Price Target to $6

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) (Nasdaq:&nbsp;IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.
Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision.
As a serial entrepreneur, Parnes has demonstrated his ability to drive innovation and growth across various high-tech sectors, including medical technology, communications and defense. Mr. Parnes is familiar with the Company and its technology, having served as an independent director of the Company since July 2021.
Mr. Parnes is a veteran executive in the medical technology industry. He co-founded and is the former chief executive officer and president at Zuta-Core Ltd. and HQL Pharmaceuticals Ltd. Mr. Parnes also served as chief operating officer at Silynx Communications Inc. as a vice president of operations at Wavion Inc. and Atrica Ltd. He also served as chief financial officer and director of business development of Printlife Ltd.

Management

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Announces The Appointment Of Mr. Tal Parnes As The New Chairman Of The Board Of Directors, Effective February 1, 2025.

BNRG

Brenmiller Europe Secures Land For A 30 MWh Thermal Energy Storage Project For A Pet Food Manufacturer

NEOG

Neogen Corporation Launched It's Igenity BCHF To Improve Overall Bovine Heart Health Standards

JP Morgan analyst Richard Shane maintains Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) with a Underweight and lowers the price target from $13.5 to $12.5.

JP Morgan Maintains Underweight on Arbor Realty Trust, Lowers Price Target to $12.5

<ul>
<li>PHINIA's direct fuel injectors will power Alpine's Alpenglow, a prototype combining automotive and motor sports excellence with sustainable approaches, including hydrogen power.</li>
<li>PHINIA, under the Delphi brand, renews its partnership with BWT Alpine Formula 1 Team, reinforcing its expert technical presence in global motorsports.</li>
<li>The expanded partnership highlights PHINIA's commitment to driving innovation in high-performance motorsports and sustainable zero-emission technologies.</li>
</ul>
PHINIA, a global leader in premium fuel systems, electrical systems, and aftermarket products, today announces two partnerships with sports car and motor racing company Alpine. It is supporting Alpine in the development of its Alpenglow hydrogen-powered prototype, as well as renewing and expanding its multi-year partnership with BWT Alpine Formula 1 Team.

PHIN

PHINIA Partners With Alpine For Alpenglow Hydrogen Prototype Using DI-CHG Injectors; Renews BWT Alpine Formula 1 Team Partnership

Biotech

General

ANIX

Anixa Biosciences Highlights 2024 Achievements And 2025 Goals: Utilized $7M, Ended With $20M Cash, Presented Phase 1 Breast Cancer Vaccine Data With 70% Immune Response, Advanced Ovarian Cancer CAR-T Program, Preparing Phase 2 Study And Broader Cancer Vaccine Development

JP Morgan analyst Ella Smith assumes TechTarget (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) with a Neutral rating and announces Price Target of $18.

Initiation

TTGT

JP Morgan Assumes TechTarget at Neutral, Announces Price Target of $18

Lakeside's Hupan Pharmaceutical Subsidiary Enters Into Distribution Agreements With Hubei Kelun To Distribute Large-Volume Parenteral Solutions

SIDU

Sidus Space Appointed Adarsh Parekh As Its New Chief Financial Officer, Effective January 27 2025

Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) ("Tantech" or the "Company") today announced that on January 16, 2025, its subsidiary,&nbsp;Gohomeway Group Inc., completed the registration of the "GOHOMEWAY" trademark in the United States. The registration, filed under application number 98967272, marks a significant milestone in the company's growth.
The "GOHOMEWAY" trademark spans a wide range of categories, including wood flooring, engineered wood flooring, and other construction materials (Class 19); furniture, cabinetry, and home storage solutions (Class 20); as well as e-commerce, advertising, and business consulting services (Class 35).
The trademark's registration provides legal protection and rights for the Gohomeway brand as Gohomeway expands its operations across the U.S. With the registration in place, Gohomeway is well-positioned to streamline its operational network development and establish a comprehensive and scalable chain system.

TANH

Tantech's Gohomeway Secured "GOHOMEWAY" U.S. Trademark Covering Multiple Categories, Enhancing Legal Protection And Expansion Efforts Across U.S.; Registration Marks Growth Milestone

ASNS

Actelis Networks Has Secured A Renewal Of Services Order Of A 6-Figure USD Value From Kenton Group

Tech

Tempus Announces National Launch Its olivia AI Personal Health Concierge App

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkairospharma.com%2F&amp;esheet=54182378&amp;newsitemid=20250121337929&amp;lan=en-US&amp;anchor=Kairos+Pharma+Ltd.&amp;index=1&amp;md5=720510cafa0a155b86a73ddb5d48023a">Kairos Pharma Ltd.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook into 2025 in a Letter to Shareholders:
Dear Kairos Pharma Shareholders,
The management team and Board of Directors of Kairos Pharma Ltd. are pleased to provide you with a brief update on the state of business and noteworthy milestones of 2024 and outlook into 2025. Last year was focused on building the foundation for our business based on breakthrough science and impactful therapeutics, while creating the fundamental infrastructure that facilitated our entry into the public markets.
Highlights from 2024 include:
<ul>
<li>Closing of our Initial Public Offering and listing of our common stock on the NYSE American stock exchange on September 16, 2024.</li>
<li>Agreement with PreCheck Health Services to further develop a biomarker panel to identify patients responsive to ENV105 to target cancer drug resistance in prostate and lung cancer patients.</li>
<li>Addition of City of Hope Cancer Center to the Company's Phase 2 clinical trial of ENV 105 for castrate-resistant prostate cancer.</li>
<li>First patient dosed in combination therapy of ENV105 and Osimertinib to improve therapy sensitivity for EGFR-driven lung cancer.</li>
<li>Participation in and presentation at various investor conferences and non-deal road shows</li>
<li>Initiation of research coverage by two leaders in the healthcare industry, Jason Kolbert of EF Hutton and Tony Butler at Rodman and Renshaw; we look forward to attracting additional research coverage of our exciting clinical programs as we move forward.</li>
<li>In 2025, we completed a PIPE transaction, raising gross proceeds of $3.5 million, ensuring continuous execution of our clinical trials and rigorous development of our key preclinical assets.</li>
<li>Expansion of patent coverage of our assets to protect our technologies domestically and internationally.</li>
</ul>
Having built the key foundations of our business, we anticipate the following key upcoming milestones for 2025, including:
<ul>
<li>Continuing to execute Phase 2 randomized clinical trial of ENV 105 in prostate cancer.</li>
<li>Continue to conduct our Phase 1 clinical trial of ENV 105 in non-small cell lung cancer.</li>
<li>Report safety data of both trials and interim efficacy data, with an initial readout of the prostate cancer safety data anticipated in the first half of 2025 and the NSCLC by year end.</li>
<li>Presenting data at national scientific meetings.</li>
<li>Pre-IND studies of KROS 101, which we also anticipate publishing.</li>
<li>Initiation of partnering discussions.</li>
</ul>
In the meantime, we continue to feel confident in the paradigm-shifting potential of our therapeutics, which are based on breakthrough science of our officers. We believe these therapeutics will show the potential to make a lasting impact by stopping the relentless spread of human neoplastic disorders.
We continue to be grateful to our partners and our shareholders and look forward to expanding upon our science, while providing value to our shareholders both in the near and long term. We look forward to continuing to provide updates on our progress.
Sincerely,
John Yu, M.D. CEO Kairos Pharma

KAPA

Kairos Pharma Outlines Key 2024 Milestones; Highlights IPO On NYSE, $3.5M PIPE Transaction, Phase 2 Trials For ENV105 Cancer Therapies; Anticipates 2025 Safety Data And Partnering Talks

IGC Pharma Appoints Former VA Governor Terry McAuliffe As A Strategic Advisor

HSAI

Hesai Technology Announces Design Wins For Chery Automobile; Says Mass Production Will Begin This Year

Berry Corporation (bry) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) ("Berry" or the "Company") today announced the appointment of Jeff Magids as the Company's Vice President, Chief Financial Officer, effective January 21, 2025. Mike Helm will continue in his position as Vice President, Chief Accounting Officer. Jeff's extensive experience, including in finance, capital markets and M&amp;A, enhances the Company's financial and strategic leadership capabilities and underscores the Company's focus on delivering sustainable, long-term growth and value creation.

Berry Announces The Appointment Of Jeff Magids As Vice President, Chief Financial Officer, Effective January 21, 2025

VIRC

Virco Mfg. Corporation Has Approved A New Share Repurchase Program For Up To $10M Of The Company's Common Stock. The Program Will Commence February 1, 2025 And Has No Time Limit

Press Releases

18 Genesis HealthCare Affiliated Centers Earn 2024 AHCA/NCAL Bronze National Quality Award

GENN

Genesis Healthcare

Comments

Genesis Healthcare

News

Latest news for Genesis Healthcare (OTC:GENN) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga